InspireMD’s $58M funding round highlights a dynamic week for MedTech investment, with capital flowing into breakthrough cardiac and health technologies. This surge supports innovations that promise to transform diagnostics, treatment, and patient care across the sector. Discover more of this week’s funding rounds in our GS MedTech Funding Tracker.
InspireMD brings in $58 million in funding for CGuard Prime carotid stent system
The PIPE, led by OrbiMed and Marshall Wace, brings in aggregate gross proceeds of $40.1 million. InspireMD also agreed to issue an aggregate of more than 16.5 million shares of common stock and, if applicable, pre-funded warrants. Priced at $2.42 per share, the exercise generated gross proceeds of $17.9 million, triggered by the company’s recent FDA premarket approval for the CGuard Prime carotid stent.
InspireMD expects the PIPE to close by Aug. 1, 2025. It plans to use proceeds to fund operations, including sales and marketing, R&D and working capital and other general purposes.
CEO Marvin Slosman
Last week’s tracker: vVardis, Shoulder Innovations, and more
Ultromics lands $55m Series C to tackle undiagnosed heart failure at scale
The round was co-led by L&G, Allegis Capital and Lightrock, with continued support from Oxford Science Enterprises, GV, Blue Venture Fund and Oxford University. Major U.S. health systems, including UChicago Medicine’s venture investment vehicle (UCM Ventures), and UPMC Enterprises also participated in the round.
The company is now expanding across the U.S. to bring that capability to the hospitals and echo labs that see the highest volume of at-risk patients, aiming to make AI-enhanced diagnostics a default step in the cardiac workup.
Founder and CEO Ross Upton, PhD
Tricuspid repair startup Versa Vascular raises $27.3 million
Versa Vascular recently closed an oversubscribed $27.3 million funding round, investor Santa Cruz Ventures announced. Santa Cruz, California-based Versa now emerges from stealth aiming to transform the treatment of tricuspid valve disease. The company hopes to take on a significant gap in the treatment of the heart valve disease.
Versa’s implant features a novel design to preserve native valve leaflets, along with an atrial skirt for secure placement.
CEO David Hovda
Sava lands $19M for world-first biosensor to disrupt real-time health monitoring
The company raised $19 million in Series A funding, following a major clinical achievement for its proprietary microsensor platform. The round was led by Balderton Capital and Pentland Ventures, with new backing from Norrsken VC and JamJar Investments, and additional support from True, Italian Founders Fund, Athletico Ventures, and Exceptional Ventures.
This latest round brings Sava’s total funding to $32 million, including previous support from angel investors, the EU, and the UK Government.
Co-Founders and Co-CEOs Rafaël Michali and Renato Circi
Maui Imaging raises $14M Series D for echo tomography tech
The company raised $14 million in a Series D financing round to support its echo tomography-based imaging technology. Acertara Acoustic Laboratories led the funding round for the Tucson, Arizona-based company. It plans to use funds to support the production, sales and marketing efforts for its imaging platform.
Maui Imaging emerged from Stealth nearly a year ago with a $4 million contract from the U.S. Dept. of Defense.
Co-Founder and CEO David Specht
Venova Technologies awarded $2.23m grant for novel contraceptive device
The startup has been awarded a $2.23M Small Business Innovation Research (SBIR) Phase II Grant from the National Institutes of Health (NIH). The SBIR program is a highly competitive, awards-based program designed to stimulate technological innovations developed by U.S. small businesses on a path to commercialization.
This Phase II award accelerates the preclinical development of Venova’s innovative cervical barrier device toward first-in-human clinical studies and brings the company’s total funding to over $5M.
Co-founder and CEO Emily Man
